Outlook Therapeutics, Inc.
OTLK · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $59 | $38 | $46 | $99 |
| - Cash | $9 | $8 | $6 | $15 |
| + Debt | $35 | $33 | $31 | $30 |
| Enterprise Value | $85 | $63 | $71 | $114 |
| Revenue | $2 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $1 | -$0 | -$0 | $0 |
| % Margin | 70.8% | – | – | 50% |
| EBITDA | -$20 | -$12 | -$22 | $6 |
| % Margin | -1,333.5% | – | – | 3,362.3% |
| Net Income | -$20 | -$46 | $17 | $6 |
| % Margin | -1,338.8% | – | – | 3,345.2% |
| EPS Diluted | -0.55 | -1.5 | 0.72 | 0.31 |
| % Growth | 63.3% | -308.3% | 132.3% | – |
| Operating Cash Flow | -$12 | -$17 | -$11 | -$17 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$12 | -$17 | -$11 | -$17 |